Novartis' ($NVS) Cosentyx may be the first next-gen psoriasis treatment to hit the U.S. market, but it certainly won't be the last--and the Swiss drugmaker knows it. So while competitors usher their own prospects down the regulatory pathway, the company is girding for the price war it envisions in its future. Report